FRESCO-2 Study Design Overview

Opinion
Video

Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
2 experts in this video
2 experts in this video
1 expert is featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.